AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06319521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride
Description: Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study NCT06319521 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: 1 milliliter of normal saline will be used for injection. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study NCT06184698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal irinotecan
Description: liposomal irinotecan 70 mg/m²
Study NCT06184698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU 2400 mg/m²
Study NCT06184698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV
Description: 5-FU 2400 mg/m²
Study NCT04888741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymoglobulin
Description: GVHD prophylaxis
Study NCT04888741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Post transplant cyclophosphamide strategy for GVHD prophylaxis
Study NCT04888741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: immunosuppressant
Study NCT04888741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: immunosuppressant
Study NCT04888741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: immunosuppressant
Study NCT04888741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: immunosuppressant
Study NCT04888741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: immunosuppressant
Study NCT05975463 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAIC
Description: hepatic artery infusion for 3-4 times.
Study NCT05975463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: hepatic artery infusion of Adebrelimab 1200mg, d1, q3w，for 3-4 times.
Study NCT05975463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: hepatic artery infusion of Bevacizumab 5mg/kg, d1, q3w, for 3-4 times.
Study NCT06519734 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire intended for patients on contraceptive modalities and use of menstrual hygiene products.~Consultation of the medical records of patients who have reported infectious complications linked to the use of intrauterine devices, tampons or menstrual cups.
Study NCT05633537 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulpectomy procedure and the clinical evaluation
Description: in this study, pulpectomy procedure was performed in a single visit and the root canals were filled with different obturating materials. The clinical follow up evaluation was carried out after three, six and twelve months after pulpectomy procedures. The teeth were clinically evaluated each follow up visit for the following clinical features: absence of spontaneous pain, no tenderness with percussion, no abnormal mobility and absence of swelling \& sinus or fistula. If the tooth exhibited any one of above clinical features, the pulpectomy was considered to be a failure (F); otherwise, it was regarded as clinical success (S).
Study NCT05633537 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulpectomy procedure and the clinical evaluation
Description: in this study, pulpectomy procedure was performed in a single visit and the root canals were filled with different obturating materials. The clinical follow up evaluation was carried out after three, six and twelve months after pulpectomy procedures. The teeth were clinically evaluated each follow up visit for the following clinical features: absence of spontaneous pain, no tenderness with percussion, no abnormal mobility and absence of swelling \& sinus or fistula. If the tooth exhibited any one of above clinical features, the pulpectomy was considered to be a failure (F); otherwise, it was regarded as clinical success (S).
Study NCT05633537 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiographic evaluation
Description: Radiographic evaluation was performed immediately after teeth restoration (base line radiograph), then after three, six and twelve months. The parallel periapical technique was performed using the rinn (XCP) periapical film holder and a long cone which was mounted to the x-ray tube. The criteria for radiographic success were no evidence of extensive pathologic root resorption, reduction or no change in pre-operative pathologic inter-radicular radiolucency and no evidence of new postoperative pathologic radiolucency.
Study NCT05633537 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiographic evaluation
Description: Radiographic evaluation was performed immediately after teeth restoration (base line radiograph), then after three, six and twelve months. The parallel periapical technique was performed using the rinn (XCP) periapical film holder and a long cone which was mounted to the x-ray tube. The criteria for radiographic success were no evidence of extensive pathologic root resorption, reduction or no change in pre-operative pathologic inter-radicular radiolucency and no evidence of new postoperative pathologic radiolucency.
Study NCT05407337 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy using Narrative Exposure Therapy (NET)
Description: There are four NET sessions, each lasting thirty minutes and defined in advance on a weekly basis. The first session is the one where the person concerned will establish his/her Life Line and start his/her life story with the peer mediator.~The second and third session will be the one where the person will continue his life story. Each session will begin with the mediator reading the story from the previous session, with the person concerned modifying the story if they wish.~The fourth session will also start with the reading of the story from the previous session and will finish the story if necessary. It will also be the occasion to give the printed story to the person concerned at the end of the session and have it signed by the mediator and the patient.~To prevent a possible risk of decompensation of the subject during the session, there will be a psychiatrist on site at the time of the NET to be available if the patient needs it.
Study NCT06527573 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active repetitive transcranial magnetic stimulation
Description: During the rTMS-active stage, treatment will be given for 7 consecutive days (two session daily). The participants will be placed in the semi-reclining position on either a normal chair or a wheelchair and each stimulation session will last 20 minutes with a frequency of 10 Hz (train duration: 1s; inter-train interval: 5s; 200 effective stimulation series; 2000 pulses at 90% of RMT).
Study NCT06527573 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham repetitive transcranial magnetic stimulation
Description: The sham coil will be used which has no magnetic field to send to the cerebral cortex while appearing to be the same shape as the active coil, with good approximation of auditory feedback.(train duration: 1s; inter-train interval: 5s; 200 effective stimulation series; 0 pulses at 90% of RMT).
Study NCT06184698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: bevacizumab 5 mg/kg
Study NCT05814263 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIS/LBB pacing
Description: 3830 lead to HIS or LBB
Study NCT05814263 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LV pacing
Description: LV lead in a CS branch
Study NCT05164770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX
Description: Zanubrutinib+R-CHOP Regimen: Zanubrutinib 160mg bid; R-CHOP: Rituximab 375mg/m2 d0, Cyclophosphamide 750mg /m2 d1, Doxorubicin 50mg /m2 or Doxorubicin liposome 30-40 mg /m2 d1, Vincristine 1.4mg /m2 or Vindesine 3mg /m2 d1, Prednisone 100mg d1-5. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.~Zanubrutinib+R-DA-EPOCH Regimen: Zanubrutinib 160mg bid; R-DA-EPOCH: Rituximab 375mg/m2 d0, Etoposide 50mg/ m2, Epirubicin 15mg/ m2, Vincristine 0.4mg/ m2, d1-4, Cyclophosphamide (CTX) 750mg/ m2 d5, Prednisone 60mg/ m2 d1-5. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.~Zanubrutinib+R-HD MTX Regimen: Zanubrutinib 160mg bid; R-HD MTX: Rituximab 375mg/m2 d0, Methotrexate 3.5g/m2 d1. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.
Study NCT05164770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-CHOP; R-DA-EPOCH; R-HD MTX
Description: R-CHOP: Rituximab 375mg/m2 d0, Cyclophosphamide 750mg/m2 d1, Doxorubicin 50mg/m2 or Doxorubicin liposome 30-40 mg /m2 d1, Vincristine 1.4mg/m2 or Vindesine 3mg/m2 d1, Prednisone 100mg d1-5. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.~R-DA-EPOCH: Rituximab 375mg/m2 d0, Etoposide 50mg/m2, Epirubicin 15mg/m2, Vincristine 0.4mg/ m2, d1-4, Cyclophosphamide (CTX) 750mg/ m2 d5, Prednisone 60mg/ m2 d1-5. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.~R-HD MTX: Rituximab 375mg/m2 d0, Methotrexate 3.5g/m2 d1. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.
Study NCT05244057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepalatide
Description: 6.3mg, s.c., qd for 48 weeks
Study NCT04711122 — intervention group
Intervention type: DRUG
Intervention: Third generation cephalosporin antibiotics
Description: Assessment of antibiotic effect
Study NCT06154915 — intervention group
Intervention type: OTHER
Intervention: medical treatments
Description: All patients will follow the medical treatments, as recommended by the multidisciplinary clinical team (for example revascularization or ulcer debriding) according to the best standard of care
Study NCT05706428 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NHFOV
Description: The neonate patients with respiratory distress will have nasal high frequency ventilation as an initial mode of respiratory support.
Study NCT05706428 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: NCPAP
Description: The neonate patients with respiratory distress will have nasal continuous positive airway pressure as an initial mode of respiratory support.
Study NCT06542276 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Thermal Vectored Pulsation
Description: The LipiFlow® (Johnson \& Johnson Vision, USA) Thermal Pulsation System, also known as vectored thermal pulsation, is a treatment that applies localized heat and pressure to the meibomian glands lining the eyelids. The device consists of a console connected to single-use, sterile devices applied to each eye known as activators. The activator includes an eye warmer with a large lens that gently sits on the conjunctiva of each eye. The activator cups the upper and lower eyelid and applies regulated, outward heat to the surface of the palpebral conjunctiva with an air bladder that intermittently provides directional, controlled massage of the eyelids to promote expression of the liquified contents.
Study NCT06540300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rTMS stimulation of right IPL
Description: The stimulation site is the right IPL (EEG International 10-20 system, electrode CP4/CP6), with a stimulation frequency of 1-Hz and intensity of 100% RMT. There are 50 pulses each time, 20 seconds each cycle, 5 seconds each, with an interval of 15 seconds, for a total of 60 cycles, a total duration of 20 minutes, and a total of 3000 pulses. Perform treatment once a day, rest for 2 days after 5 consecutive days of treatment, for a total of 2 weeks, and receive 10 treatments.
Study NCT05053919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Schumann resonance sleep device
Description: A Schumann resonance sleep device would stably output the composite frequency of a the Schumann resonance frequency (7.83 Hz) wave, theta wave, and delta wave.~The subjects were asked to use the device (place it next to the bed facing the subject's head, turn it on about one hour before going to bed every night, and turn it off after getting up the next day) every night for four weeks.
Study NCT05053919 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sleep device
Description: A Placebo sleep device is an instrument with the same appearance and operation as the Schumann resonance sleep device, but does not output any frequency wave.~The subjects were asked to use the device (place it next to the bed facing the subject's head, turn it on about one hour before going to bed every night, and turn it off after getting up the next day) every night for four weeks.
Study NCT05186922 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM326
Description: CM326 injection
Study NCT05186922 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06339021 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OCT-guided PCI
Description: OCT-guided PCI based on MLD MAX algorithm
Study NCT06339021 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional angiography-based PCI
Description: Conventional angiography-based PCI
Study NCT06339021 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional angiography-based PCI
Description: Conventional angiography-based PCI
Study NCT06339021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAPT de-escalation
Description: Aspirin and clopidogrel 30 days after DES implantation
Study NCT06339021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: default DAPT regimen
Description: Aspirin and ticagrelor 30 days after DES implantation
Study NCT06339021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: default DAPT regimen
Description: Aspirin and ticagrelor 30 days after DES implantation
Study NCT06308913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB081776
Description: INCB081776 will be given orally on a daily basis. The highest safe/tolerable dose and schedule will be established by the ongoing phase 1 clinical trial of INCB081776 plus INCBMGA00012 (NCT03522142), which is 120 mg daily.
Study NCT06308913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Immune checkpoint blockade with anti-PD-1 (Pembrolizumab) will be given as 200 mg IV on cycle 1 day 15 and cycle 1 day 36. Starting from cycle 2, pembrolizumab will be given on day 1 on each subsequent cycle.
Study NCT06308913 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative RT
Description: Palliative RT will be given as either 24 Gy in 3 fractions (8 Gy per fraction) or 20 Gy in 5 fractions (4 Gy per fraction). The palliative radiation therapy dose will be determined based on the clinical judgment of the treating radiation oncology physician. Palliative RT must be completed between cycle 1 day 29 to cycle 1 day 33. After completion of palliative radiation therapy, patients will continue with additional cycles of INCB081776 and pembrolizumab until disease progression, intolerance to the combination regimen, or patient withdrawal.
Study NCT06568302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SerpinPC
Description: Administered as SC injection.
Study NCT04853004 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV2 antibody measurement
Description: Blood samples for serology, collected immediately prior to and five to ten weeks after vaccination against SARS-CoV2, to be analyzed for the presence of SARS-CoV-2 antibodies.
Study NCT05194397 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside
Description: Investigators will use (Good Manufacturing Process) GMP-grade 300 mg capsules of the dietary supplement nicotinamide riboside (ChromaDex, Irvine CA).~NR is distributed by ChromaDex, Inc., Irvine, CA. NR is available as 300 mg capsules.~The dietary supplement will be re-labeled by the Hospital of the University of Pennsylvania (HUP) Investigational Drug Service according to FDA regulations, including subject and physician name and NR or Placebo 300 mg capsules.
Study NCT05194397 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The matched placebo will contain the same excipients without the active supplement and is generally recognized as safe. The placebo will be covered in an identical capsule (NR will be covered in the same capsule)
Study NCT05194397 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The matched placebo will contain the same excipients without the active supplement and is generally recognized as safe. The placebo will be covered in an identical capsule (NR will be covered in the same capsule)
Study NCT05194397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: The exercise program consists of at-home training sessions and will include aerobic and strengthening components designed to progress persons gradually to 150-300 minutes of the equivalent of moderate aerobic activity, and twice weekly strengthening over 16 weeks. For aerobic training, the eventual intensity and duration goal (adapted for each person as necessary) will be for persons to train at 70-80% of peak 2MSPT heart rate 20-45 minutes 3-5 days/week. For resistance exercises the goal will be a load/weight that results in fatigue after 3 sets of 10-12 repetitions on 8-10 exercises 2 days/week.
Study NCT06204432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Citrate
Description: Those randomized to the Sodium Citrate arm will use 1 mL of 2.5% sodium citrate (3.5g/140 mL, pH 7.4, 298 mOsmol/L), 0.5 mL in each nostril, twice a day via an atomizer followed by olfactory training.
Study NCT06204432 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Those randomized to the Normal Saline arm will use 1 mL of normal saline, 0.5 mL in each nostril, twice a day via an atomizer followed by olfactory training.
Study NCT06204432 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Olfactory Training Kit - The Olfactory Kit, by AdvancedRx
Description: All participants, regardless of study arm they are randomized to, will participate in olfactory training twice a day after use of their nasal spray
Study NCT06204432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olfactory Training Kit - The Olfactory Kit, by AdvancedRx
Description: All participants, regardless of study arm they are randomized to, will participate in olfactory training twice a day after use of their nasal spray
Study NCT05675384 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS Active Treatment
Description: Using a 7-day/week wearable TENS device controlled by a Smart Phone App combined with moderate intensity lifestyle therapy,
Study NCT05675384 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: Using the sham (control) device combined with a moderate intensity lifestyle follow-up
Study NCT05110950 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No suction EBUS-TBNA
Description: The needle is moved from a side to side of the lymphnode for 15 times. Each lymphnode is sampled three times.~The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs.
Study NCT05110950 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Passive suction through dedicated EBUS-TBNA syringe
Description: The needle is moved from a side to side of the lymphnode for 15 times. Each lymphnode is sampled three times.~The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs.
Study NCT05110950 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual applied suction EBUS-TBNA through a pistol-grip syringe holder
Description: The needle is moved from a side to side of the lymphnode for 15 times. Each lymphnode is sampled three times.~The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs..
Study NCT05244057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Hepalatide
Description: s.c., qd for 48 weeks
Study NCT05244057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide Tablets
Description: 25mg, p.o., qd for 48 weeks
Study NCT05244057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tenofovir Alafenamide Tablets
Description: 25mg, p.o., qd for 48 weeks